On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...